European Hematology Association Congress

Side Effects of BGB-16673 Appear Manageable in Early CLL Study

June 27th 2025, 1:00pm

Video

An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns, per Dr. Lydia Scarfò.

Jaktinib Further Improves Spleen Volume in Myelofibrosis

June 21st 2023, 1:00pm

Article

Jaktinib significantly improved spleen volume reduction rates compared with hydroxyurea in intermediate- to high-risk myelofibrosis.

Chemoimmunotherapy Responses May Allow for Omission of Radiotherapy in Lymphoma

June 19th 2023, 9:00pm

Article

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.

Pre- or Post-Transplant Xospata Shows Relapse-Free Survival Benefit in AML Group

June 15th 2023, 3:00pm

Article

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

More CAR-T Cell Therapies Will ‘Ease Out the Shortage’

June 13th 2023, 3:00pm

Video

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

Standard Approach for Inactive, Early CLL Remains a Wait-and-Watch Strategy

June 12th 2023, 9:00pm

Article

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

Jakafi Improves Symptoms, Spleen Volume in Myelofibrosis

June 12th 2023, 3:00pm

Article

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.

Maintenance Darzalex Regimen Promising in Post-Transplant Myeloma

June 10th 2023, 6:00pm

Article

Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.

Iclusig With Chemo ‘Should Be Standard of Care’ for ALL Subset

June 10th 2023, 3:00pm

Article

Iclusig plus reduced-intensity chemotherapy led to improved outcomes for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia, and should be the new standard of care, one expert said.

Study Examines Calquence in Older CLL Population

June 9th 2023, 9:00pm

Article

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.